41 new IPOs priced on Nasdaq for the third quarter, taking the Exchange to 140 year-to-date, Nelson Griggs, SVP of the Global Corporate Client Group tells TheStreet’s Jill Malandrino. This compares to 126 for all of 2013. Griggs says that the Nasdaq is seeing broad-based sector listings, with a concentration in consumer, consumer tech and biotech. The momentum is expected to continue through Q4, with 40-50 deals expected. A big part of the IPO strength in terms of listings has been the strength in the underlying market. Griggs explains that 2015 visibility will be more clear around November, but for now metrics suggest it could be another solid year for IPOs on Nasdaq.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.